{"commentary":{"count":3,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":3},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"ICARUS-LUNG01","nct_id":"NCT04940325","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=icarus-lung01-nct04940325. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"ICARUS-LUNG01","arms":[{"description":"All patients included in the study will receive DS-1062a at a dose of 6 mg/kg every 3 weeks until progression or until unacceptable toxicity","label":"DS-1062a","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo"],"completion_date":{"date":"2028-09","type":"ESTIMATED"},"conditions":["Metastatic Lung Cancer","Advanced Non Small Cell Lung Cancer","Unresectable Non-small Lung Cancer"],"enrollment":{"count":100,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"DS-1062a","type":"DRUG"}],"last_update":"2025-11-26","lead_sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","official_title":"Phase 2, Open Label Study of DS-1062a, an Anti-TROP-2-Antibody-Drug Conjugate (ADC), in Patients With Advanced and/or Unresectable Non-Small Cell Lung Cancer (NSCLC), With Biomarker Analysis to Characterize Response to Therapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-04","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Evaluation of objective response rate (ORR) based on investigator assessment","timeFrame":"During treatment period, an average of 4 months"}],"references":[],"start_date":{"date":"2021-05-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT04940325"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/icarus-lung01-nct04940325"}